NRG-GY024

Open to Accrual

Return to Protocol Table

Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial

Principal Investigator

Brian Slomovitz, MD

Status

Open to Accrual

Date Opened To Accrual

August 31 2021

Disease Site

Gynecologic [GY]

Cervix

Phase

Developmental Therapeutics

Primary Objective

The primary objective of this study is to investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early-stage vulvar cancer patients with a macrometastasis (>2mm) and/or extracapsular extension in the Sentinel Lymph Node (SLN). The secondary objective is to evaluate the short and long-term morbidity associated with the SLN procedure and chemoradiation.

Patient Population

Early stage vulvar cancer with macrometastasis and/or extracapsular extension in the SLN

Target Accrual

Forms

Investigator Resources

NRG-GY024 Investigator Skill Verification.docx

Regulatory Resources

Study Memos

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.